Analysts See $-0.48 EPS for Allena Pharmaceuticals, Inc. (ALNA)

November 11, 2018 - By Tina Thibodeau

Analysts expect Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) to report $-0.48 EPS on December, 13.They anticipate $3.01 EPS change or 86.25 % from last quarter’s $-3.49 EPS. After having $-0.42 EPS previously, Allena Pharmaceuticals, Inc.’s analysts see 14.29 % EPS growth. The stock decreased 5.81% or $0.5 during the last trading session, reaching $8.11. About 10,989 shares traded. Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company has market cap of $168.30 million. The company's lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It currently has negative earnings. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases.

More recent Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) news were published by: Nasdaq.com which released: “Allena Pharmaceuticals Highlights Ongoing Efforts to Address Rare and Severe Metabolic Disorders Affecting the …” on October 18, 2018. Also Nasdaq.com published the news titled: “Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update” on November 07, 2018. Globenewswire.com‘s news article titled: “Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November” with publication date: November 06, 2018 was also an interesting one.

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.